UPENDS
28.12.2022 10:56:41 CET | Business Wire | Press release
UPENDS, an e-cigarette brand that prioritizes users’ experience and aims to become the favorite brand for vapers, has recently released its brand new next-gen mesh coil technology and UpBAR GT, the world’s first car concept disposable vape equipped with the next-gen mesh coil.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221227005002/en/
(Photo: Business Wire)
What Does the Next-gen Mesh Coil Mean to the Vape Market?
With the surge of the disposable vape market, countless manufacturers and brands influx into this track, pushing technology innovation quickly. Mesh coil, the key tech of disposable vapes, becomes the essential of tech innovation, which profoundly influences performance like flavor reproduction and puffs. It is obvious that products with stronger next-gen mesh coils will be more competitive in the market.
Next-gen Mesh Coil Comes with Significant Improvements in Performance.
Since the release of its “Mesh Coil is the Future” brand proposition, UPENDS has been dedicated to the innovation of mesh coil technology and has made many breakthroughs. After lab tests and adjustments, UPENDS next-gen mesh coil has been invented successfully. “Compared with traditional mesh coils, its flavor reproduction increased by 38%, puffs increased by 33% and energy efficiency increased by 36% with the same e-liquid capacity”, said Doctor WU, the Chief Product Officer of UPENDS. “We are so excited to release the next-gen mesh coil, and we believe that our customers will be satisfied with the strong performance and longevity it brings.”
UPENDS Makes A Comprehensive Breakthrough in Mesh Coil Technology.
Not only optimizing the coil, UPENDS has also upgraded technologies of the whole cotton coil platform for better performance and quality control. It features a V-shaped air inlet design that can accelerate aerosol delivery, decrease condensate and provide stronger smoke, compared with normal straight channels. Meanwhile, there’s literally no possibility of burnt tastes and oil leakage thanks to its industry-first Tesla value, unique separate air exchange and e-liquid supply channels and multi-layer seal leakage-proof. In addition, it adopts fully-automated manufacturing process technology, aiming to guarantee both production efficiency and stable high quality.
UpBAR GT with Next-gen Mesh Coil is Coming in January 2023.
So what does the next-gen mesh coil bring to UPENDS? UpBAR GT, the first disposable vape equipped with this technology will be the answer. As the “World’s First Car Concept Disposable Vape”, UpBAR GT seeks inspiration from sports cars and stands out from the crowd with its streamlined design and V-shaped grille decorations. GT is the abbreviation of Grand Touring, a type of car designed for high speed and long-distance driving, which also implies the features such as high quality, stability, security and more of UpBAR GT. In addition, there is an eco-friendly version using recycled materials.
About UPENDS
Founded in 2019, UPENDS is an e-cigarette brand dedicated to the field of Electronic Nicotine Delivery Systems. The good reputation of UPENDS as a leading e-cigarette brand in Europe attributes to its excellent manufacturing technology and quality, simple design, and cost-effective features. Currently, UPENDS is expanding its global development. UPENDS persistent pursuit is to prioritize users’ experience and to be Vaper's favorite. For more information, please visit www.upends.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221227005002/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
